{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:11:05Z","timestamp":1789668665282,"version":"4.0.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K08CA283001"],"award-info":[{"award-number":["1K08CA283001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1K08CA289935-01A1"],"award-info":[{"award-number":["1K08CA289935-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR003097"],"award-info":[{"award-number":["KL2 TR003097"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005301","name":"American College of Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["T32 HS013852"],"award-info":[{"award-number":["T32 HS013852"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>For breast cancer patients with clinically node-positive (cN+) and residual disease after neoadjuvant chemotherapy (NAC), axillary lymph node dissection (ALND) remains the standard of care, though alternative strategies may be selected by multidisciplinary teams in certain cases. This study evaluated factors associated with omission of ALND for cN+ patients who were pathologically node-positive after NAC (ypN+).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective observational study, the National Cancer Database was queried for patients with clinical T1\u2013T4, N1\u2013N3 breast cancer from 2016 to 2021 who received NAC and were subsequently ypN+. Axillary procedures were categorized as sentinel lymph node biopsy (SLNB) alone, SLNB followed by ALND (SLNB\u2009+\u2009ALND), or ALND alone. Logistic regression identified factors associated with omission of ALND after SLNB, adjusting for sociodemographic, geographic, and clinical variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 38,559 patients, axillary interventions were SLNB alone (\n                      <jats:italic>n<\/jats:italic>\n                      = 7,131, 18.49%), SLNB+ALND (\n                      <jats:italic>n<\/jats:italic>\n                      = 14,247, 36.95%), and ALND alone (\n                      <jats:italic>n<\/jats:italic>\n                      = 17,179, 44.55%). Over the study period, SLNB alone and SLNB\u2009+\u2009ALND increased while ALND alone decreased. Compared with academic programs, patients treated at comprehensive community, integrated network, and community programs had greater odds of SLNB alone compared with SLNB+ALND (odds ratio [OR] 1.32, 95% confidence interval [CI] 1.22\u20131.43; OR 1.17, 95% CI 1.07\u20131.27; OR 1.54, 95% CI 1.33\u20131.78, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There has been de-escalation of ALND after initial SLNB for cN+ breast cancer patients found to be ypN+. This suggests that providers may be extrapolating evidence supporting SLNB alone to populations in which it has not yet been thoroughly studied or are omitting ALND in anticipation of ongoing clinical trial results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19968-5","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:11:28Z","timestamp":1782475888000},"page":"9035-9048","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy"],"prefix":"10.1245","volume":"33","author":[{"given":"Nicole","family":"Rademacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily A.","family":"Gutnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy K.","family":"Broman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"issue":"1","key":"19968_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-022-00383-4","volume":"8","author":"SP Shubeck","year":"2022","unstructured":"Shubeck SP, Morrow M, Dossett LA. De-escalation in breast cancer surgery. NPJ Breast Cancer. 2022;8(1):1\u20134. https:\/\/doi.org\/10.1038\/s41523-022-00383-4.","journal-title":"NPJ Breast Cancer"},{"issue":"6","key":"19968_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375. https:\/\/doi.org\/10.1001\/jama.2011.90.","journal-title":"JAMA"},{"issue":"12","key":"19968_CR3","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7.","journal-title":"Lancet Oncol"},{"issue":"12","key":"19968_CR4","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1200\/JCO.22.01565","volume":"41","author":"SAL Bartels","year":"2023","unstructured":"Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial. J Clin Oncol. 2023;41(12):2159\u201365. https:\/\/doi.org\/10.1200\/JCO.22.01565.","journal-title":"J Clin Oncol"},{"issue":"13","key":"19968_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Tvedskov TF, Ryd\u00e9n L, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med. 2024;390(13):1163\u201375. https:\/\/doi.org\/10.1056\/NEJMoa2313487.","journal-title":"N Engl J Med"},{"issue":"14","key":"19968_CR6","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361. https:\/\/doi.org\/10.1001\/jama.2013.278932.","journal-title":"JAMA"},{"issue":"7","key":"19968_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9.","journal-title":"Lancet Oncol"},{"issue":"3","key":"19968_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258\u201364. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827.","journal-title":"J Clin Oncol"},{"issue":"2","key":"19968_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10549-018-5004-7","volume":"173","author":"JM Classe","year":"2019","unstructured":"Classe JM, Loaec C, Gimbergues P, et al. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study. Breast Cancer Res Treat. 2019;173(2):343\u201352. https:\/\/doi.org\/10.1007\/s10549-018-5004-7.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"19968_CR10","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","volume":"27","author":"MA Piltin","year":"2020","unstructured":"Piltin MA, Hoskin TL, Day CN, Davis J, Boughey JC. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer. Ann Surg Oncol. 2020;27(12):4795\u2013801. https:\/\/doi.org\/10.1245\/s10434-020-08900-0.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"19968_CR11","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1245\/s10434-020-09211-0","volume":"28","author":"SM Wong","year":"2021","unstructured":"Wong SM, Basik M, Florianova L, et al. Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer. Ann Surg Oncol. 2021;28(5):2621\u20139. https:\/\/doi.org\/10.1245\/s10434-020-09211-0.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"19968_CR12","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","volume":"47","author":"S Kahler-Ribeiro-Fontana","year":"2021","unstructured":"Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. Eur J Surg Oncol. 2021;47(4):804\u201312. https:\/\/doi.org\/10.1016\/j.ejso.2020.10.014.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"19968_CR13","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.ejso.2015.11.019","volume":"42","author":"V Galimberti","year":"2016","unstructured":"Galimberti V, Ribeiro Fontana SK, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment. Eur J Surg Oncol (EJSO). 2016;42(3):361\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2015.11.019.","journal-title":"Eur J Surg Oncol (EJSO)"},{"issue":"10","key":"19968_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. JCO. 2016;34(10):1072\u20138. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094.","journal-title":"JCO"},{"issue":"6","key":"19968_CR15","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","volume":"25","author":"TA Moo","year":"2018","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;25(6):1488\u201394. https:\/\/doi.org\/10.1245\/s10434-018-6429-2.","journal-title":"Ann Surg Oncol"},{"key":"19968_CR16","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer V6.2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf"},{"issue":"7","key":"19968_CR17","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1377\/hlthaff.2015.1490","volume":"35","author":"DH Howard","year":"2016","unstructured":"Howard DH, Soulos PR, Chagpar AB, Mougalian S, Killelea B, Gross CP. Contrary to conventional wisdom, physicians abandoned a breast cancer treatment after a trial concluded it was ineffective. Health Aff. 2016;35(7):1309\u201315. https:\/\/doi.org\/10.1377\/hlthaff.2015.1490.","journal-title":"Health Aff"},{"issue":"1","key":"19968_CR18","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.surg.2021.12.025","volume":"172","author":"KK Broman","year":"2022","unstructured":"Broman KK, Richman J, Bhatia S. Evidence and implementation gaps in management of sentinel node\u2013positive melanoma in the United States. Surgery. 2022;172(1):226\u201333. https:\/\/doi.org\/10.1016\/j.surg.2021.12.025.","journal-title":"Surgery"},{"issue":"4","key":"19968_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamasurg.2020.6942","volume":"156","author":"T Wang","year":"2021","unstructured":"Wang T, Bredbeck BC, Sinco B, et al. Variations in persistent use of low-value breast cancer surgery. JAMA Surg. 2021;156(4):353\u201362. https:\/\/doi.org\/10.1001\/jamasurg.2020.6942.","journal-title":"JAMA Surg"},{"issue":"1","key":"19968_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.amepre.2023.01.039","volume":"65","author":"SA Nowak","year":"2023","unstructured":"Nowak SA, Wilcock AD, Sprague BL. Spillover after mammography guideline change: evidence from state-level trends. Am J Prevent Med. 2023;65(1):122\u20135. https:\/\/doi.org\/10.1016\/j.amepre.2023.01.039.","journal-title":"Am J Prevent Med"},{"key":"19968_CR21","doi-asserted-by":"publisher","first-page":"116484","DOI":"10.1016\/j.amjsurg.2025.116484","volume":"247","author":"N Rademacher","year":"2025","unstructured":"Rademacher N, McLeod MC, Williams CP, et al. Association between travel burden and surgical timeliness for women with breast cancer in Georgia. Am J Surg. 2025;247:116484. https:\/\/doi.org\/10.1016\/j.amjsurg.2025.116484.","journal-title":"Am J Surg"},{"issue":"3","key":"19968_CR22","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cncr.20785","volume":"103","author":"NJO Birkmeyer","year":"2005","unstructured":"Birkmeyer NJO, Goodney PP, Stukel TA, Hillner BE, Birkmeyer JD. Do cancer centers designated by the National Cancer Institute have better surgical outcomes? Cancer. 2005;103(3):435\u201341. https:\/\/doi.org\/10.1002\/cncr.20785.","journal-title":"Cancer"},{"issue":"21","key":"19968_CR23","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1002\/cncr.29576","volume":"121","author":"J Wolfson","year":"2015","unstructured":"Wolfson J, Sun CL, Wyatt L, Hurria A, Bhatia S. Impact of care at comprehensive cancer centers on outcome: results from a population-based study. Cancer. 2015;121(21):3885\u201393. https:\/\/doi.org\/10.1002\/cncr.29576.","journal-title":"Cancer"},{"issue":"4","key":"19968_CR24","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1245\/s10434-021-11304-3","volume":"29","author":"MC Schroeder","year":"2022","unstructured":"Schroeder MC, Gao X, Lizarraga I, Kahl AR, Charlton ME. The impact of commission on cancer accreditation status, hospital rurality and hospital size on quality measure performance rates. Ann Surg Oncol. 2022;29(4):2527\u201336. https:\/\/doi.org\/10.1245\/s10434-021-11304-3.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"19968_CR25","doi-asserted-by":"publisher","first-page":"e2429563","DOI":"10.1001\/jamanetworkopen.2024.29563","volume":"7","author":"K Chan","year":"2024","unstructured":"Chan K, Palis BE, Cotler JH, et al. Hospital accreditation status and treatment differences among black patients with colon cancer. JAMA Netw Open. 2024;7(8):e2429563. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.29563.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"19968_CR26","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1245\/s10434-019-07323-w","volume":"26","author":"LN Shulman","year":"2019","unstructured":"Shulman LN, Browner AE, Palis BE, et al. Compliance with cancer quality measures over time and their association with survival outcomes: the Commission on Cancer\u2019s experience with the quality measure requiring at least 12 regional lymph nodes to be removed and analyzed with colon cancer resections. Ann Surg Oncol. 2019;26(6):1613\u201321. https:\/\/doi.org\/10.1245\/s10434-019-07323-w.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"19968_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.amjsurg.2020.03.035","volume":"220","author":"ZV Fong","year":"2020","unstructured":"Fong ZV, Chang DC, Hur C, et al. Variation in long-term oncologic outcomes by type of cancer center accreditation: an analysis of a SEER-Medicare population with pancreatic cancer. Am J Surg. 2020;220(1):29\u201334. https:\/\/doi.org\/10.1016\/j.amjsurg.2020.03.035.","journal-title":"Am J Surg"},{"issue":"11","key":"19968_CR28","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1158\/1055-9965.EPI-25-0311","volume":"34","author":"N Duncan","year":"2025","unstructured":"Duncan N, Amu-Nnadi C, Montgomery KB, et al. An ecologic analysis of the association of regional cancer center presence with cancer mortality for the continuous United States. Cancer Epidemiol Biomark Prev. 2025;34(11):1907\u201313. https:\/\/doi.org\/10.1158\/1055-9965.EPI-25-0311.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"13","key":"19968_CR29","doi-asserted-by":"publisher","first-page":"8813","DOI":"10.1245\/s10434-024-16143-6","volume":"31","author":"JN Limberg","year":"2024","unstructured":"Limberg JN, Jones T, Thomas SM, et al. Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy. Ann Surg Oncol. 2024;31(13):8813\u201320. https:\/\/doi.org\/10.1245\/s10434-024-16143-6.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"19968_CR30","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.surg.2023.08.039","volume":"175","author":"JN Whitrock","year":"2024","unstructured":"Whitrock JN, Carter MM, Leonard LD, Lewis JD, Shaughnessy EA, Heelan AA. Axillary management in breast cancer after neoadjuvant chemotherapy in the modern era: a national cancer database analysis. Surgery. 2024;175(3):687\u201394. https:\/\/doi.org\/10.1016\/j.surg.2023.08.039.","journal-title":"Surgery"},{"issue":"11","key":"19968_CR31","doi-asserted-by":"publisher","first-page":"6401","DOI":"10.1245\/s10434-023-13759-y","volume":"30","author":"JC Boughey","year":"2023","unstructured":"Boughey JC, Yu H, Dugan CL, et al. Changes in surgical management of the axilla over 11 years: report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial. Ann Surg Oncol. 2023;30(11):6401\u201310. https:\/\/doi.org\/10.1245\/s10434-023-13759-y.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"19968_CR32","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1245\/s10434-018-6578-3","volume":"25","author":"AU Barron","year":"2018","unstructured":"Barron AU, Hoskin TL, Boughey JC. Predicting non-sentinel lymph node metastases in patients with a positive sentinel lymph node after neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(10):2867\u201374. https:\/\/doi.org\/10.1245\/s10434-018-6578-3.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"19968_CR33","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.clbc.2020.04.008","volume":"20","author":"MM Kozak","year":"2020","unstructured":"Kozak MM, Horst KC, Gutkin PM, et al. Patterns of failure in women who have residual nodal disease after neoadjuvant chemotherapy for breast cancer according to extent of lymph node surgery. Clin Breast Cancer. 2020;20(5):431\u20138. https:\/\/doi.org\/10.1016\/j.clbc.2020.04.008.","journal-title":"Clin Breast Cancer"},{"issue":"16_suppl","key":"19968_CR34","doi-asserted-by":"publisher","first-page":"e12624","DOI":"10.1200\/JCO.2023.41.16_suppl.e12624","volume":"41","author":"C Hlavin","year":"2023","unstructured":"Hlavin C, Balogun Z, Lavage DR, et al. Can axillary lymph node dissection (ALND) be omitted in patients with breast cancer with persistent axillary disease after neoadjuvant chemotherapy? J Clin Oncol. 2023;41(16_suppl):e12624. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e12624.","journal-title":"J Clin Oncol"},{"issue":"8","key":"19968_CR35","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1245\/s10434-025-17405-7","volume":"32","author":"A Weiss","year":"2025","unstructured":"Weiss A, Agnese DM, Al-Hilli Z, et al. An overview of the importance of neoadjuvant systemic therapy for breast cancer patients: from the Society of Surgical Oncology and the American Society of Breast Surgeons. Ann Surg Oncol. 2025;32(8):5453\u201366. https:\/\/doi.org\/10.1245\/s10434-025-17405-7.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"19968_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(25)00598-4","volume":"27","author":"G Montagna","year":"2026","unstructured":"Montagna G, Alvarado M, Myers S, et al. Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07\/microNAC): an international, retrospective cohort study. Lancet Oncol. 2026;27(1):57\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(25)00598-4.","journal-title":"Lancet Oncol"},{"issue":"5","key":"19968_CR37","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1245\/s10434-025-16973-y","volume":"32","author":"JC Boughey","year":"2025","unstructured":"Boughey JC, Yu H, Switalla K, et al. Oncologic outcomes with de-escalation of axillary surgery after neoadjuvant chemotherapy for breast cancer: results from > 1500 patients on the I-SPY2 clinical trial. Ann Surg Oncol. 2025;32(5):3278\u201391. https:\/\/doi.org\/10.1245\/s10434-025-16973-y.","journal-title":"Ann Surg Oncol"},{"key":"19968_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.21037\/tbcr-24-45","volume":"6","author":"A Fancellu","year":"2025","unstructured":"Fancellu A, Giuliani G, Mulas S, Contini AM, Ariu ML, Sanna V. De-escalation of axillary treatment in early breast cancer\u2014a narrative review of current trials. Transl Breast Cancer Res. 2025;6:5. https:\/\/doi.org\/10.21037\/tbcr-24-45.","journal-title":"Transl Breast Cancer Res"},{"key":"19968_CR39","unstructured":"Alliance for Clinical Trials in Oncology. A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy. clinicaltrials.gov; 2025. Accessed 21 Jan 2026. https:\/\/clinicaltrials.gov\/study\/NCT01901094."},{"key":"19968_CR40","unstructured":"Garcia-Tejedor A. Axillary lymph node dissection versus axillary radiotherapy in breast cancer patients with positive sentinel node after neoadjuvant therapy: a multicenter randomized study. clinicaltrials.gov; 2026. Accessed 10 Mar 2026. https:\/\/clinicaltrials.gov\/study\/NCT04889924."},{"key":"19968_CR41","unstructured":"University Hospital, Basel, Switzerland. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A Multicenter Randomized Phase III Trial. clinicaltrials.gov; 2025. Accessed 21 Jan 2026. https:\/\/clinicaltrials.gov\/study\/NCT03513614."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19968-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19968-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19968-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:52:02Z","timestamp":1789667522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19968-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["19968"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19968-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or other conflicts of interest to report related to the conduct of this work.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}